Efficacy of oncolytic mutants targeting pRb and p53 pathways is synergistically enhanced when combined with cytotoxic drugs in prostate cancer cells and tumor xenografts. [electronic resource]
Producer: 20110321Description: 1311-25 p. digitalISSN:- 1557-7422
- Adenovirus E1A Proteins -- genetics
- Adenovirus E1B Proteins -- genetics
- Adenoviruses, Human -- drug effects
- Animals
- Antineoplastic Agents -- pharmacology
- Cell Cycle -- drug effects
- Cell Death -- drug effects
- Cell Line, Tumor
- Combined Modality Therapy
- Docetaxel
- Flow Cytometry
- Gene Expression
- Genes, p53
- Humans
- Immunoblotting
- Male
- Mice
- Mice, Nude
- Mitoxantrone -- pharmacology
- Neoplasm Transplantation
- Oncolytic Virotherapy -- methods
- Oncolytic Viruses -- drug effects
- Polymerase Chain Reaction
- Prostatic Neoplasms -- drug therapy
- Retinoblastoma Protein -- metabolism
- Taxoids -- pharmacology
- Transplantation, Heterologous
- Tumor Suppressor Protein p53 -- metabolism
- Virus Replication -- drug effects
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.